R&D | October 12, 2025
Merck unveils new HIV treatment and prevention data at EACS 2025
Merck will showcase results in innovative solutions in HIV treatment and prevention
Merck will showcase results in innovative solutions in HIV treatment and prevention
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated
